BNET Industries

Vertex Pharmaceuticals Inc.

(VRTX) is in the Pharma Industry

Market Cap:$6.9B
Last Fiscal Year Sales:$175.5M
  • Public
  • US
Dow Jones Description

We are in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, our lead drug candidate, is an oral hepatitis C protease inhibitor and one of the most advanced of a new class of antiviral treatments in clinical development that targets hepatitis C virus, or HCV, infection. Telaprevir is being evaluated in a fully-enrolled registration program focused on treatment-naive and treatment-experienced patients with genotype 1 HCV. We currently intend to file a new drug application, or NDA, for telaprevir in the United States in the second half of 2010, assuming the successful completion of our ongoing registration program. We also are developing, among other compounds, VX-770, a drug candidate for the treatment of patients with cystic fibrosis, or CF. In the first half of 2009, we expect to begin a registration program for VX-770 that focuses on CF patients with the G551D mutation in the gene responsible for CF. HCV infection is a life-threatening disease that affects approximately 3.2 million people in the United States and causes inflammation of the liver, significantly increasing the risk that a patient will develop liver failure or liver cancer. Genotype 1 HCV is the most prevalent HCV genotype in North America, the European Union and Japan. ...

Number of Employees 1,310
Contact Information

130 Waverly St

Cambridge, Massachusetts 02139-4252

vpharm.com

1 617 444 6100

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration

    11/09/09 - Joint Venture / Alliance - View Story

  • Morgan Stanley Upgrades Vertex VRTX to Overweight

    11/04/09 - Bond / Stock Rating - View Story

  • Vertex Says More Than 80% Of Hepatitis C Patients Treated In Study C208 Achieved SVR...

    10/31/09 - Joint Venture / Alliance - View Story

  • Vertex Pharmaceuticals up after loss

    10/28/09 - Financial Announcement - View Story

  • UPDATE 2-Vertex sells future payments, sees wider '09 loss

    9/30/09 - Mgmt. Change Leaving - Other - View Story

  • Vertex lowers '09 earnings guidance by $100M

    10/01/09 - Financial Announcement - View Story

  • Vertex Pharma To Begin Phase 2 Proof-of-concept Clinical Trial For VX-509; Sees Wider Loss In...

    9/30/09 - Mgmt. Change Leaving - Vice President - View Story

  • Vertex secures $155M from debt financing for telaprevir

    10/02/09 - New Investment - View Story

  • Altus moves to retire $6.8M Vertex claim

    8/17/09 - Mgmt. Change Leaving - Vice President - View Story

  • Vertex Pharma Q2 Loss Widens, Sees Higher-than Expected FY09 Loss - Update

    8/05/09 - Financial Announcement - View Story

  • Vertex Pharmaceuticals Incorporated VRTX JOBS Grabs $105M in Amended Telaprevir Deal with Mitsubishi Tanabe Pharma...

    7/31/09 - New Investment - View Story

  • Vertex Pulls a Wimpy

    7/10/09 - Licensing / Contract - View Story

  • Vertex Pharmaceuticals' board of directors joined by Jeffrey Leiden and Dennis Winger

    7/08/09 - Board Member - Entering - View Story

News & Analysis

vertex pharmaceuticals inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Matthew W. Emmens CEO
David E Shaw President
Freda C. Lewis-Hall Executive Vice President, Medicines Development and Chief Medical Officer
Ian F. Smith Executive Vice President and Chief Financial Officer
John Alam Executive Vice President, Med. Dev. Group & Cmo
Kurt C Graves Executive Vice President, Chief Commercial Officer
Peter Mueller Executive Vice President Drug Innov.& Realiz, Cso
Valerie Andrews Chief Compliance Officer
Victor A. Hartmann Executive Vice President, Strategic & Corp Development
Amit K Sachdev Senior Vice President, Public Policy,Gov Affairs
Kenneth Boger General Counsel & Senior Vice President
Lisa Kelly Senior Vice President, Human Resources
Richard C Garrison Senior Vice President and Catalyst
Iain Buchanan Managing Director, Vertex Pharmaceuticals Limited & Vice President, European Operations
Johanna Messina Power Vice President & Controller
Kerry Reinertsen Vice President, Corp and Business Development
Michael Partridge Vice President, Investor Relations
Paul M. Silva Vice President and Corporate Controller (Principal Accounting Officer)
Josh Boger Founder
Joshua Boger Founder
Lora Pike Associate Director, Investor Relations
Majda Benhayoun Director of Program and Portfolio Management
Patricia Farrell Director of Public Relations
Paul Anderson Director, Advisory
Stephanie Marrus Director, Corp Communications
Zachry Barber Media Relations Manager
Carol Werther
Lisa Kelly-Croswell
Bruce Sachs Director
Stuart J. Collinson Director

Board of Directors

Name (plus bio) Position
Charles A. Sanders Chairman of the Board
Eric K Brandt Chair
Roger W. Brimblecombe Committee Chair for Management Development and Compensation Committee
Donald R Conklin Board of Directors
Eugene H. Cordes Board of Directors
Eve E. Slater Board of Directors
Mathew W. Emmens Board of Directors

Mr. Emmens is Chairman and CEO of Vertex. He has over 33 years of experience in the pharmaceutical industry, including Shire Pharmaceuticals Group plc and businesses operated by Merck KGaA and Merck & Co. He became our Chairman, CEO and President in 2009 and has been a member of our Board of Directors since 2004. Mr. Emmens is the Chairman of the Board of Directors of Shire and was its Chief Executive Officer from March 2003 through June 2008. Before joining Shire in 2003, Mr. Emmens served as president of Merck KGaA’s global prescription pharmaceuticals business in Darmstadt, Germany. In 1999, he joined Merck KGaA and established EMD Pharmaceuticals, its United States prescription pharmaceutical business. Mr. Emmens held the position of President and Chief Executive Officer at EMD Pharmaceuticals from 1999 to 2001. Earlier, Mr. Emmens held various positions, including Chief Executive Officer, at Astra Merck, Inc. as well as several positions at Merck & Co., Inc. Mr. Emmens received a B.S. degree in business management from Fairleigh Dickinson University.

Organization Position Status
Vertex Pharmaceuticals Incorporated CEO Current
Incyte Corporation Chief Executive Officer, Chairman of the Executive Committee Current
The S.H.I.R.E Chief Executive Officer Current
Vertex Pharmaceuticals Incorporated President Current
Shire plc Chairman Current
Vertex Pharmaceuticals Incorporated Chairman Current
Vertex Pharmaceuticals Incorporated Board of Directors Current
Shire Acquisition Inc. Board of Directors Current
The S.H.I.R.E Board of Directors Current
Vertex Pharmaceuticals Incorporated Committee Member Current
Emd Pharmaceuticals, Inc. Chief Executive Officer Former
Shire Acquisition Inc. Chief Executive Officer Former
Shire plc Chief Executive Officer Former
Emd Pharmaceuticals, Inc. President Former
Fairleigh Dickinson University B.S. Degree In Business Management Former
Merck & Co. Inc. Former

Organization Position Status
Vertex Pharmaceuticals Incorporated President Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Executive Vice President, Medicines Development and Chief Medical Officer Current
Pfizer Inc. Senior Vice President & Chief Medical Officer Current
Bristol-Myers Squibb Company Senior Vice President, Medical Affairs Former
Pharmacia Corporation Vice President, Research & Development Former
Eli Lilly and Company Product Team Leader Former
Howard University Hospital Medical Doctorate Former
The Johns Hopkins University Bachelor of Arts & Sciences Degree Former

Ian Smith joined Vertex in November 2001. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. As Vertex’s CFO, Mr. Smith holds responsibility for a wide variety of core functions at Vertex, including Finance, Strategic Communications, Information Systems and Operations. Mr. Smith is also a member of the Executive Team at Vertex. Mr. Smith received a B.A. with honors in Accounting and Finance from Manchester Metropolitan University. Mr. Smith is a current member of the American Institute of Certified Public Accountants, the Institute of Chartered Accountants of England and Wales, and the Financial Executives Institute. Mr. Smith is a member of the Board of Directors of Acorda Therapeutics, Inc, Epix Pharmaceuticals, Inc. and TolerRx Inc. Additionally, he is a board member of the Massachusetts Biotechnology Council and is Chair of its Policy Committee.

Organization Position Status
Vertex Pharmaceuticals Incorporated Executive Vice President and Chief Financial Officer Current
Vertex, Inc. Executive Vice President Current
Infinity Pharmaceuticals, Inc Chair Current
Acorda Therapeutics, Inc. Board of Directors Current
TolerRx, Inc. Board of Directors Current
Predix Pharmaceuticals Holdings, Inc. Board of Directors Current
Vertex Pharmaceuticals Incorporated Board of Directors Current
Prohost Biotechnology Board of Directors Current
American Institute of Certified Public Accountants Member Current
Vertex, Inc. Chief Financial Officer Former
Vertex Pharmaceuticals Incorporated Senior Vice President Former
Vertex, Inc. Senior Vice President Former
Vertex, Inc. Vice President Former
Life Science!, Inc Partner Former
Ernst & Young partner Former
Manchester Metropolitan University B.A. with honors in accounting Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Executive Vice President, Med. Dev. Group & Cmo Current
Vertex Pharmaceuticals Incorporated Senior Vice President Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Executive Vice President, Chief Commercial Officer Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Executive Vice President Drug Innov.& Realiz, Cso Current
Vertex Pharmaceuticals Incorporated Senior Vice President Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Chief Compliance Officer Current
Vertex, Inc. Current
Columbia Laboratories, Inc. Board of Directors Current
Vertex Pharmaceuticals Incorporated Vice President Former
Vertex Pharmaceuticals Incorporated Deputy General Counsel Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Executive Vice President, Strategic & Corp Development Current
Bioexec Ventures, LLC Executive Vice President, Strategic & Corporate Development, Vertex Pharmaceuticals, Inc. Current
Biotech Turnaround Fund Bv Current
Vertex, Inc. Senior Vice President Former
Boehringer Ingelheim Corporation Vice President Former
Sandoz Pharmaceuticals Corporation Vice President Former
University of Bonn Doctor of Medicine Former
Macalester College Bachelor of Science in Biology Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Senior Vice President, Public Policy,Gov Affairs Current
Vertex Pharmaceuticals Incorporated Board of Directors Current

Organization Position Status
Vertex Pharmaceuticals Incorporated General Counsel & Senior Vice President Current
Vertex Pharmaceuticals Incorporated Board of Directors Current
Boston College J.D. Former
Duke University A.B. In History Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Senior Vice President, Human Resources Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Senior Vice President and Catalyst Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Managing Director, Vertex Pharmaceuticals Limited & Vice President, European Operations Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Vice President & Controller Current
Vertex Pharmaceuticals Incorporated Controller Former
Vertex Pharmaceuticals Incorporated Board of Directors Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Vice President, Corp and Business Development Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Vice President, Investor Relations Current
Vertex Pharmaceuticals Incorporated Director, Corp Communications Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Vice President and Corporate Controller (Principal Accounting Officer) Current

Organization Position Status
Vertex, Inc. Founder Current
Vertex Pharmaceuticals Incorporated Founder Current
Progressive Business Leaders Network Board of Directors Current
Wesleyan University Trustee Current
Vertex Pharmaceuticals Incorporated Chief Executive Officer Former
Vertex Pharmaceuticals Incorporated President Former
Harvard University Doctorate Degrees In Chemistry Former
Harvard University Master's Former
Wesleyan University Bachelor of Arts In Chemistry and Philosophy Former

Joshua S. Boger , Ph.D., has served as a member of our board of directors since December 2005. He was a founder of Vertex Pharmaceuticals, Inc., a biotechnology company, and has served as Vertex's Chief Executive Officer since January 2000 and also as its President since February 2006. He also served as Chairman of Vertex's board of directors from January 2000 to May 2006. Dr. Boger received his B.A. in chemistry and philosophy from Wesleyan University and his M.S. and Ph.D. degrees in chemistry from Harvard University.

Organization Position Status
Vertex, Inc. Chief Executive Officer Current
Nehi Founder Current
Vertex Pharmaceuticals Incorporated Founder Current
Massachusetts High Technology Council, Inc Chairman Current
Nehi Secretary Current
The Hastings Center Board of Directors Current
Activbiotics Inc. Board of Directors Current
Progressive Business Leaders Network Board of Directors Current
Vertex Pharmaceuticals Incorporated Board of Directors Current
Wesleyan University Trustee Current
Vertex Pharmaceuticals Incorporated Director and Chief Executive Officer (Principal Executive Officer) Former
Activbiotics Inc. Dr. Boger Is Chairman and Chief Executive Officer of Vertex Pharmaceuticals Former
Vertex Pharmaceuticals Incorporated President Former
Vertex, Inc. Chief Scientific Officer Former
Vertex, Inc. Founder Former
Vertex Pharmaceuticals Incorporated Chairman Former
Harvard University Ph.D. Degree In Chemistry Former
Harvard University Master's Former
Wesleyan University Bachelor of Arts In Chemistry and Philosophy Former
Harvard University B.A. In Chemistry Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Associate Director, Investor Relations Current
Vertex Pharmaceuticals Incorporated Manager, Investor Relations Former

Majda Benhayoun, Ph.D. is currently Director of Program and Portfolio Management at Vertex Pharmaceuticals and has been working in drug development for the past 3 years. Prior to joining Vertex, Majda worked in Clinical Project Management for more than 15 years, with her first 11 years at Aventis Pharma, previously Rhone-Poulenc Rorer, and then 4 years at PAREXEL International where she held a position of Clinical Project Director. Majda has extensive experience in project management both strategic and operational in early and late stages of drug development in various therapeutic areas, some of them being CNS, inflammation, or immunology. As Clinical Program Manager, Majda has a broad experience in the concepts of clinical trials including planning and execution of clinical trials from single site Phase I to large and complex multinational Phase III trials concluding in NDA/MAA filing.

Organization Position Status
Vertex Pharmaceuticals Incorporated Director of Program and Portfolio Management Current
Barnett International Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Director of Public Relations Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Director, Advisory Current
Vertex Pharmaceuticals Incorporated Director, Advisory Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Director, Corp Communications Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Media Relations Manager Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Current

Organization Position Status
Vertex Pharmaceuticals Incorporated Current

Organization Position Status
The University of North Carolina Trustee Current
marketRx Inc. Current
Feinstein Kean Healthcare Current
Vertex Pharmaceuticals Incorporated Chairman of the Board Current
Venrock Associates Chairman of the Board of Directors Current
Foundation for the National Institutes of Health Chairman, Executive Committee Current
Icagen, Inc. Chairman Current
Project Hope Chairman Former
Drug Safety Alliance, Inc. Board of Directors Current
Icagen, Inc. Board of Directors Current
Kendle International Inc. Director Current
Cephalon, Inc. Board of Directors Current
Genentech, Inc. Director Current
Pharmacopeia Drug Discovery Inc. Board of Directors Current
Radius Ventures, LLC Board of Directors Current
Csis Inc Board of Directors Current
Cardioxyl Pharmaceuticals, Inc. Board of Directors Current
Trimeris, Inc. Director Current
Personalized Medicine Coalition Board of Directors Current
Epiphany Biosciences, Inc. Board of Directors Current
Staffmark Board of Directors Current
Scios, Inc. Director Current
Reata Pharmaceuticals, Inc Board of Directors Current
Vrtx Board of Directors Current
Science & Technology Group CEO Former
Massachusetts General Hospital General Director Former
Harvard Medical School director of Massachusetts General Hospital Former
Massachusetts Gen Hospital General Director Former
Harvard Medical School Professor of Medicine Former
Meredith College trustee Former
Scios Inc. Former
New York Academy of Sciences Chairman Former
Vertex Pharmaceuticals Incorporated Board of Directors Current
Genaera Corporation Board of Directors Former
Reynolds Metals, Inc. Board of Directors Former
Squibb Corporation Board Member Former
Biopure Corporation Director Former
Massachusetts General Hospital Director Former
Squibb Corporation Vice Chairman Former
The University of Texas Southwestern Medical School M.D. Former
The University of Texas Former

Organization Position Status
Broadcom Corporation Chief Financial Officer Current
Broadcom Korea Chief Financial Officer Current
Vertex Pharmaceuticals Incorporated Chair Current
Dentsply International Inc. Director Current
Vertex Pharmaceuticals Incorporated Committee Member Current
The Boston Consulting Group, Inc. Vice President Former
The Boston Consulting Group, Inc. Partner Former
The Boston Consulting Group, Inc. senior member Former
Allergan, Inc. Former
Vertex Pharmaceuticals Incorporated Board of Directors Former
Harvard University M.B.A. Former
Harvard Business School M.B.A. Former
Massachusetts Institute of Technology bachelor of science in chemical engineering Former
Massachusetts, Inc. B.S. In Chemical Engineering Former

Organization Position Status
Drug Discovery World Consultant Editor Current
Vertex Pharmaceuticals Incorporated Committee Chair for Management Development and Compensation Committee Current
Psimedica Chairman Current
Vertex Pharmaceuticals Incorporated Director Current
Psivida Limited Board of Directors Current
Vertex Pharmaceuticals Incorporated Committee Member Current
University of Bristol D.Sc. Degrees In Pharmacology Former

Array

Organization Position Status
Nantero Board of Directors Current
Parascale Board of Directors Current
Carrier Iq Board of Directors Current
Cedar Point Communications, Inc. Board of Directors Current
Accelerated Cure Project Board of Directors Current
Acopia Networks, Inc. Board of Directors Current
Celerica, Inc. Director Current
BigBand Networks, Inc. Board of Directors Current
Vertex Pharmaceuticals Incorporated Director Current
M2Z Networks, Inc Board of Directors Current
Icontrol Incorporated Director Current
Vertex Pharmaceuticals Incorporated Committee Member Current
Stratus Computer, Inc. CEO Former
Stratus Inc CEO Former
Stratus Inc President Former
Stratus Computer, Inc. President Former
Ascend Executive Vice President Former
Bay Networks executive vice president Former
Ascend General Manager Former
Bay Networks General Manager Former
AT&T Bell Laboratories NA Former
Riverdelta Networks, Inc. Board Member Former
Flarion Technologies, Inc. Board Member Former
Arrowpoint Corporation Board of Directors Former
Cport.Com, LLC Board of Directors Former
American Internet Corporation Board of Directors Former
Flarion Technologies, Inc. Investor Former
Riverdelta Networks, Inc. Investor Former
Cornell University master of engineering in electrical engineering Former
Northeastern University MBA Degree Former
Bucknell University BS Degree In Electrical Engineering Former
Northeastern University BSEE degrees Former

Organization Position Status
Alfacell Corp Member, Board of Directors Current
Bio Transplant Incorporated Member, Board of Directors Current
Cytotherapeutics, Inc. Board of Directors Current
Onconase Board of Directors Current
Vertex Pharmaceuticals Incorporated Board of Directors Current
inVentiv Health Inc. Board of Directors Current
Schering-Plough Corporation Executive Vice President Former
Schering-Plough Corporation Senior Executive Former
Schering-Plough Corporation Chairman, Health Care Products Division Former
Schering-Plough Healthcare Products Corp. Chairman Former
Rutgers University MBA degree Former
Williams College B.A. Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Board of Directors Current
Vertex Pharmaceuticals Incorporated Committee Member Current
Vitae Pharmaceuticals, Inc. Chairman Former
Brandeis University Ph.D. In Biochemistry Former

Organization Position Status
Theravance, Inc. Board of Directors Current
Vertex Pharmaceuticals Incorporated Board of Directors Current
Phase Forward Incorporated Board of Directors Current
AnorMED, Inc. Board of Directors Current
Merck & Co. Inc. chief safety officer Former
Merck & Co. Inc. Vice President, and later Senior Vice President of Clinical and Regulatory Development Former
Merck & Co. Inc. Executive Director of Biochemistry and Molecular Biology Former
Merck & Co. Inc. Senior Director Former
VaxGen, Inc. Board of Directors Former
Vassar College A.B. Degree Former

Organization Position Status
Vertex Pharmaceuticals Incorporated Board of Directors Current

Organization Position Status
Tioga Pharmaceuticals, Inc. Chairman & Acting CEO Current
Cabrellis Pharmaceuticals Corporation Partner, Forward Ventures Current
Southern California Inc Partner Current
Forward Ventures Partner Current
Oxagen Limited Non Executive Director Current
Novacardia, Inc Member of the Board of Directors Current
Forward Ventures Board of Directors Current
Oxagen Limited Director Current
Affinium Pharmaceuticals, Inc Director Current
Geneohm Sciences, Inc. Director Current
Cabrellis Pharmaceuticals Corporation Board of Directors Current
Vertex Pharmaceuticals Incorporated Director Current
Technology Vision Group LLC Board of Directors Current
Asteres Director Current
Forward Ventures Member Current
Vertex Pharmaceuticals Incorporated Committee Member Current
Vertex Pharmaceuticals Incorporated Chief Executive Officer Former
Aurora Biosciences Corporation Chief Executive Officer Former
Aurora Biosciences Corporation President Former
Vertex Pharmaceuticals Incorporated President Former
The Boston Consulting Group, Inc. consultant Former
Aurora Biosciences Corporation Chairman of the Board Former
Vertex Pharmaceuticals Incorporated Chairman Former
Conforma Therapeutics Corporation Chairman of the Board Former
Tioga Pharmaceuticals, Inc. Director Former
Conforma Therapeutics Corporation Director Former
University of Oxford PhD. In Physical Chemistry Former
Harvard University MBA Former
Harvard Business School MBA Former

Executive News

  • Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals' Board of Directors

    Pharma Live - 7/09/09 - View Story

  • Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals` Board of Directors

    Reuters - 7/07/09 - View Story

  • Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals' Board of Directors

    Forbes.com - 7/07/09 - View Story

  • Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals Board of Directors

    Business Wire - 7/07/09 - View Story

  • Sarah Reed Rejoins Charles River Ventures as General Counsel

    PR Newswire - 6/04/09 - View Story

advertisement
     VRTX $38.54 -0.38 (-0.98% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 2,151,840
Shares Outstanding 181.19M
Market Cap 7.0B
Year High 41.75
Year Low 19.87
Earnings Per Share -3.84
P/E Ratio -10.04
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement
Click Here